(lp0
S"BRIEF-Amgen Inc reports four-year follow-up results from Repatha Osler-1 study Reuters - Mar 14, 2017 ... * Toyota, electric machinery makers offer smaller base pay raise * Unions made same demands as one year ago * Big firms offer far less than union demands * Hikes 'far from enough' to boost growth - economist  By Tetsushi Kajimoto TOKYO ..."
p1
aS"Why to Keeping Eye on Wynn Resorts, Limited , Amgen Inc. ? StockNewsJournal - 21 hours ago Amgen Inc. , maintained return on investment for the last twelve months at 11.95, higher than what Reuters data shows regarding industry's average."
p2
aS"BRIEF-Amgen inc says to present new kyprolis and xgeva data Reuters - Mar 1, 2017 Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news&nbsp;..."
p3
aS"Mizuho Analysts Give Amgen, Inc.  a $195.00 Price Target Chaffey Breeze - 19 hours ago Mizuho set a $195.00 price objective on Amgen, Inc.  in a report released on Friday morning. The firm currently has a buy rating on the medical research company's stock.Sii Investments Inc. WI Increases Stake in Amgen, Inc.  - BNB Daily Why Amgen  Stock Rallied After Q4 Earnings Release? - Nasdaq"
p4
aS"Amgen Inc. : From Top to Bottom StockNewsJournal - Mar 8, 2017 Amgen Inc.  is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $177.38, down from yesterday's close by -1.16%.Amgen, Inc.  Earns Outperform Rating from BMO Capital Markets - Chaffey BreezeMartingale Asset Management LP Sells 3733 Shares of Amgen, Inc.  - BNB Daily "
p5
aS"Amgen Sues Coherus Over Chemo Drug Trade Secrets Law360  - Mar 8, 2017 Law360, New York  -- Amgen Inc. on Friday sued Coherus Biosciences Inc., which is seeking approval of a biosimilar of Amgen's chemotherapy drug Neulasta, telling a California court that Coherus has been poaching its&nbsp;..."
p6
aS'What Makes Amgen A Compelling Buy In 2017? Seeking Alpha - Feb 17, 2017 Amgen expects to meet or even surpass its financial commitments for 2018. The company has been returning significant value to shareholders through dividends and share repurchases.Should You Buy Amgen, Inc.  Stock? 3 Pros, 3 Cons - Investorplace.comDigging Up the Facts on Amgen Inc.  - StockNewsJournal'
p7
aS'Oppenheimer Reiterates Outperform Rating and $189 PT on Amgen Inc. (AMGN ... StreetInsider.com - Feb 28, 2017 Oppenheimer and Co. analyst Leah Cann reiterates Outperform rating and $189 price target on Amgen Inc. , as the company announced positive results from overall survival interim analysis of the phase 3 Endeavor Trial.'
p8
aS"Amgen's Repatha Meets Primary Endpoint in Phase III Study Yahoo Finance - Mar 14, 2017 Biotech major, Amgen, Inc. AMGN announced positive data from a phase III study evaluating its PCSK9 inhibitor, Repatha in patients who were receiving apheresis to help control their low-density lipoprotein cholesterol .Amgen's Repatha lowers need for cholesterol-lowering procedure - Daily Mail"
p9
aS'Why Investors remained confident on Amgen Inc. , Dollar General ... StockNewsJournal - Mar 9, 2017 Amgen Inc.  have shown a high EPS growth of 20.50% in the last 5 years and has earnings decline of 13.10% yoy. Analysts have a mean recommendation of 2.30 on this stock (A rating of less than 2 means buy, hold within the 3 range, sell within&nbsp;...'
p10
a.